Detection of recurrent pancreatic cancer: Comparison of FDG-PET with CT/MRI

Pancreatology

Volumn 5, Issue 2-3, 2005, Pages 266-272

  Ruf, Juri ^a,b   Hänninen, Enrique Lopez ^a   Oettle, Helmut ^b   Plotkin, Michail ^a   Pelzer, Uwe ^b   Stroszczynski, Christian ^a   Felix, Roland ^a   Amthauer, Holger ^a  

^a PET Centre Berlin   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Computed tomography; Fluorine 18 fluoro 2 deoxy D glucose positron emission tomography; Imaging; Magnetic resonance imaging; Pancreas cancer recurrence

Indexed keywords

CA 19-9 ANTIGEN; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER CYTODIAGNOSIS; CANCER PAIN; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTED TOMOGRAPHIC COLONOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; LIVER METASTASIS; MALE; MALIGNANT TRANSFORMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CARCINOMA; PERITONEUM METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; WEIGHT REDUCTION;

EID: 19944377522     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000085281     Document Type: Article

References (25)

1. Oettle H, Riess H: Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer. Cancer 2002;95(suppl):912-922.
2. Jacobs AD: Gemcitabine-based therapy in pancreas cancer: Gemcitabine-docetaxel and other novel combinations. Cancer 2002;95(suppl): 923-927.
3. Mortele KJ, Lemmerling M, de Hemptinne B, De Vos M, De Bock G, Kunnen M: Postoperative findings following the Whipple procedure: Determination of prevalence and morphologic abdominal CT features. Eur Radiol 2000;10: 123-128.
4. Safi F, Schlosser W, Falkenreck S, Beger HG: Prognostic value of CA 19-9 serum course in pancreatic cancer. Hepatogastroenterology 1998;45:253-259.
5. Barkin JS, Goldstein JA: Diagnostic approach to pancreatic cancer. Gastroenterol Clin North Am 1999;28:709-722.
6. Franke C, Klapdor R, Meyerhoff K, Schauman M: 18-FDG positron emission tomography of the pancreas: Diagnostic benefit in the follow-up of pancreatic carcinoma. Anticancer Res 1999;19:2437-2442.
7. Jadvar H, Fischman AJ: Evaluation of pancreatic carcinoma with FDG PET. Abdom Imaging 2001;26:254-259.
8. Higashi T, Saga T, Nakamoto Y, Ishimori T, Fujimoto K, Doi R, Imamura M, Konishi J: Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) - Usefulness and limitations in 'clinical reality'. Ann Nucl Med 2003; 17:261-279.
9. Lopez Hanninen E, Amthauer H, Hosten N, Ricke J, Bohmig M, Langrehr J, Hintze R, Neuhaus P, Wiedenmann B, Rosewicz S, Felix R: Prospective evaluation of pancreatic tumors: Accuracy of MR imaging with MR cholangiopancreatography and MR angiography. Radiology 2002;224:34-41.
10. Hanbidge AE: Cancer of the pancreas: The best image for early detection - CT, MRI, PET or US? Can J Gastroenterol 2002;16:101-105.
11. Delbeke D: Oncological applications of FDG PET imaging. J Nucl Med 1999;40:1706-1715.
12. Koyama K, Okamura T, Kawabe J, Nakata B, Chung KH, Ochi H, Yamada R: Diagnostic usefulness of FDG PET for pancreatic mass lesions. Ann Nucl Med 2001;15:217-224.
13. Zimny M, Bares R, Fass J, Adam G, Cremerius U, Dohmen B, Klever P, Sabri O, Schumpelick V, Buell U: Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: A report of 106 cases. Eur J Nucl Med 1997;24:678-682.
14. Stollfuss JC, Glatting G, Friess H, Kocher F, Berger HG, Reske SN: 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: Value of quantitative image interpretation. Radiology 1995;195:339-344.
15. Rosemurgy AS, Serafini FM: New directions in systemic therapy of pancreatic cancer. Cancer Control 2000;7:437-451.
16. Ghaneh P, Kawesha A, Howes N, Jones L, Neoptolemos JP: Adjuvant therapy for pancreatic cancer. World J Surg 1999;23:937-945.
17. Hirai I, Kimura W, Ozawa K, Kudo S, Suto K, Kuzu H, Fuse A: Perineural invasion in pancreatic cancer. Pancreas 2002;24:15-25.
18. Higashi T, Tamaki N, Torizuka T, Nakamoto Y, Sakahara H, Kimura T, Honda T, Inokuma T, Katsushima S, Ohshio G, Imamura M, Konishi J: FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med 1998;39:1727-1735.
19. Reske SN, Grillenberger KG, Glatting G, Port M, Hildebrandt M, Gansauge F, Beger HG: Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med 1997;38:1344-1348.
20. Nakata B, Nishimura S, Ishikawa T, Ohira M, Nishino H, Kawabe J, Ochi H, Hirakawa K: Prognostic predictive value of 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer. Int J Oncol 2001; 19:53-58.
21. Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, Mozley PD, Rossman MD, Albelda SM, Alavi A: Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001;42:1412-1417.
22. Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Doi R, Hosotani R, Imamura M, Konishi J: Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 2000;89:2547-2554.
23. Lyshchik A, Higashi T, Nakamoto Y, Fujimoto K, Doi R, Imamura M, Saga T: Dual-phase (18)F-fluoro-2-deoxy-d-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging 2004 [Epub ahead of print].
24. Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF: Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): A meta-analysis. Radiology 2002;224: 748-756.
25. Sobin LH, Wittekind C (eds): UICC-TNM Classification of Malignant Tumours, ed 5. New York, Wiley-Liss, 1997.